Core Concepts
Over one fifth of American adults reported using hemp-derived cannabinoids, with concerns raised about product safety and regulation.
Abstract
The research provides insights into the usage of hemp-derived cannabinoids among American adults, highlighting concerns about product safety and regulation. Key points include:
- 25.2% of adults reported using emerging cannabinoids, including CBD and delta-8 THC.
- Concerns exist about the lack of regulation for these products, posing risks of unknown contaminants.
- Usage rates for other hemp-derived products like CBG and CBN were lower.
- Delta-8 THC, known for psychotropic effects, raised particular concerns due to associated adverse effects.
- Legalization of hemp cultivation led to a surge in hemp-derived products without federal regulation.
- Medical cannabis legalization was linked to lower odds of delta-8 THC usage.
- FDA advisory highlighted issues with mislabeling and contaminants in cannabinoid products.
- Patients often view nonpsychotropic cannabinoids as natural remedies, despite concerns about psychoactive effects.
- Study authors received grants from various entities, including government and research organizations.
Stats
25.2% of adults reported past-year use of any emerging cannabinoid, including delta-8 THC.
11.9% reported using delta-8 THC, 5.2% reported using CBG, and 4.4% reported using CBN.
Residents in states where medical cannabis is legal had 56% lower odds of using delta-8 THC.
Quotes
"If someone is picking up one of these products to use medically, and it ends up having heavy metals and pesticides and it doesn't even have the active ingredient in it, that is not good." - Kevin F. Boehnke, PhD
"My official response to patients who ask me for my opinion is that I don't have enough scientific background to give an opinion: If you think it helps you and you have no side effects, then I'm not going to tell you to stop." - Alice Kuo, MD, PhD